DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06324461

GLUMINS

RecruitingPhase 4

GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery

Glucagon-like Peptide-1 Receptor Agonist for Reduction of Myocardial Injury After Non-Cardiac Surgery

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

3

Recruiting sites

2

Enrollment

372

estimated

Study population

Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•MINS

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06324461
Org study IDGLUMINS

Timeline

Milestones

Study start2024-03-20actual
Study first posted2024-03-22actual
Last update posted2026-05-04actual
Primary completion2028-12-31estimated
Study completion2028-12-31estimated

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Perioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age ≥ 18 years
•Planned elective intermediate to high risk non-cardiac surgery
•Anticipated to remain hospitalized for at least one night after surgery
•Voluntarily agrees to participate by providing written informed consent

Exclusion criteria

•History of symptomatic hypoglycemia within 1 month of recruitment
•History of pancreatitis
•Diabetic retinopathy
•Personal or family history of medullary thyroid carcinoma (MTC)
•Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
•Acute coronary syndrome, decompensated heart failure, cardiogenic shock, or myocarditis within 1 month of recruitment
•Stroke or transient ischemic attack within 1 month of recruitment
•Known severe liver disease (Child-Pugh B or C)
•Stage 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) by Modified Diet in Renal Disease (MDRD) equation < 15 mL/min)
•Recent use of GLP-1 RA within 1 month of recruitment
•Known allergy or hypersensitivity to GLP-1 RA
•Women of childbearing age who are not taking effective contraception, or who are pregnant or breast-feeding
•Use of Dipeptidyl peptidase-4 inhibitor(DPP4i)

Endpoints (26)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiovascular outcomes
12
Other clinical outcomes
5
Safety / tolerability / PK
3
Renal / kidney
2
Cardiometabolic biomarkers
2
Heart failure
1
Other (unclassified)
1

Cardiovascular outcomes

12 endpoints
Secondary/protocol endpoint

Proportion of patients with composite of non-fatal MINS, non-fatal stroke or cardiovascular mortality

Time frame:Within 30 days of randomization

Expanded / custom MACE composite

composite event, event

componentsNon-fatal MI, Non-fatal stroke, Cardiovascular death

Secondary/protocol endpoint

Proportion of patients with MINS who do not fulfill the 4th universal definition of myocardial infarction

Time frame:Within 30 days of randomization

Myocardial infarction (any)

threshold achievement, improvement

SNOMED 22298006

Secondary/protocol endpoint

Proportion of patients with myocardial infarction according to the 4th universal definition of myocardial infarction

Time frame:Within 30 days of randomization

Myocardial infarction (any)

threshold achievement, event

SNOMED 22298006

Secondary/protocol endpoint

Proportion of patients with ischemic stroke

Time frame:Within 30 days of randomization

Ischemic stroke

threshold achievement, event

SNOMED 230690007

Secondary/protocol endpoint

Proportion of patients with cardiovascular death

Time frame:Within 30 days of randomization

Cardiovascular death

threshold achievement, event

Secondary/protocol endpoint

Proportion of patients with all-cause mortality

Time frame:Within 30 days of randomization

All-cause death

threshold achievement, event

SNOMED 419620001

Secondary/protocol endpoint/low confidence

Mean days alive and out of hospital

Time frame:Within 30 days of randomization

descriptive, improvement

Secondary/protocol endpoint

Clinically important atrial fibrillation

Time frame:Within 30 days of randomization

Atrial-fibrillation composite

composite event, event

Other/protocol endpoint

Proportion of patients with coronary revascularization

Time frame:Within 30 days of randomization

Coronary revascularization

threshold achievement, event

SNOMED 415070008

Other/protocol endpoint

Proportion of patients who require readmission for cardiovascular conditions

Time frame:Within 30 days of randomization

threshold achievement, event

Other/protocol endpoint/low confidence

Proportion of patients with non-fatal cardiac arrest

Time frame:Within 30 days of randomization

threshold achievement, event

Other/protocol endpoint

Proportion of patients requiring amputation

Time frame:Within 30 days of randomization

Major amputation

threshold achievement, event

Heart failure

1 endpoint
Other/protocol endpoint

Proportion of patients who require hospitalization for heart failure

Time frame:Within 30 days of randomization

Heart-failure hospitalization

threshold achievement, event

SNOMED 84114007

Renal / kidney

2 endpoints
Other/protocol endpoint

Proportion of patients with acute renal failure fulfilling Kidney Disease Improving Global Outcomes (KDIGO) criteria

Time frame:Within 30 days of randomization

threshold achievement, event

Other/protocol endpoint

Proportion of patients with acute renal failure requiring dialysis

Time frame:Within 30 days of randomization

Kidney-replacement therapy

threshold achievement, event

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Mean peak troponin T concentration

Time frame:During the period of index hospitalization up to 3 days

concentration, descriptive

Secondary/protocol endpoint

Mean area under curve of troponin T concentration

Time frame:During the period of index hospitalization up to 3 days

concentration, descriptive

Safety / tolerability / PK

3 endpoints
Secondary/protocol endpoint

Clinically significant hypoglycaemia

Time frame:Within 30 days of randomization

descriptive, event

Other/protocol endpoint

Proportion of patients with International Society on Thrombosis and Haemostasis (ISTH) major bleeding

Time frame:Within 30 days of randomization

threshold achievement, event

Other/protocol endpoint

Proportion of patients with infection or sepsis

Time frame:Within 30 days of randomization

threshold achievement, event

Other clinical outcomes

5 endpoints
Primary/protocol endpoint

Proportion of patients with MINS

Time frame:Within 72 hours after surgery

threshold achievement, event

Other/protocol endpoint

Proportion of patients who develop pulmonary embolism and/or deep vein thrombosis

Time frame:Within 30 days of randomization

threshold achievement, event

Other/protocol endpoint

Proportion of patients with bleeding independently associated with mortality following noncardiac surgery (BIMS)

Time frame:Within 30 days of randomization

threshold achievement, event

Other/protocol endpoint

Mean length of intensive care unit stay

Time frame:During index hospitalization up to 1 week

descriptive

Other/protocol endpoint/low confidence

Mean days alive without need for intensive care support

Time frame:During index hospitalization up to 3 days

descriptive

Other (unclassified)

1 endpoint
Other/protocol endpoint/low confidence

Mean length of stay

Time frame:During index hospitalization up to 3 days

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.